RT Journal Article
SR Electronic
T1 Features of FeNO-high asthma phenotype
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3711
DO 10.1183/13993003.congress-2021.PA3711
VO 58
IS suppl 65
A1 Francesca Bertolini
A1 Andrea Elio Sprio
A1 Elisa Riccardi
A1 Andrea Baroso
A1 Vitina Carriero
A1 Fabio Luigi Massimo Ricciardolo
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3711.abstract
AB Introduction: In asthma exhaled nitric oxide (FeNO) is considered a clinical-relevant biomarker for evaluating airway T2 inflammation. FeNO is related to severe and uncontrolled asthma and predicted exacerbations.Aims and objectives: The study aims to describe asthma phenotypes based on FeNO levels.Methods: 320 non-smoking asthmatics were retrospectively stratified according to FeNO values (FeNO-low, ≤25 ppb; FeNO-mid, 26-50 ppb; FeNO-high, >50 ppb). Clinical, functional and blood parameters in stable mild-to-severe asthmatics were extrapolated from the chart data.Results: FeNO-high showed higher prevalence in rhinitis (p <0.01 vs FeNO-low) and nasal polyposis (p <0.05 vs FeNO-mid, and p <0.01 vs FeNO-low), however they had a lower prevalence of GERD and arthropathy (p <0.05) than FeNO-low. The FeNO-high exhibited a greater airflow obstruction (TI%, p <0.05 vs FeNO-low), although displaying a better reversibility (∆FVC, p <0.05, and ∆FEV1, p <0.01) than FeNO-mid and FeNO-low. FeNO-high revealed a worsening in daily activity limitations (p <0.05 vs FeNO-mid). Concerning blood biomarkers, FeNO-high showed higher blood eosinophilia (p <0.001) and a higher percentage of patients with blood eosinophils >300cells/µL (p <0.001 vs FeNO-low and p <0.05 vs FeNO-mid). Finally, FeNO-high displayed a higher prevalence of highly-frequent exacerbators (≥3 asthma exacerbations per year, p <0.01, OR=3.2).Conclusions: The main features of FeNO-high asthma phenotype are elevated blood eosinophilia, greater reversible airflow obstruction and higher risk of frequent exacerbations associated with upper airways comorbidities. FeNO monitoring is a non-invasive test useful for patients who may also benefit from personalized therapeutic strategies.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3711.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).